Silence Therapeutics : Condensed consolidated income statement (unaudited) - Form 6-K
Condensed consolidated income statement Three months ended ...
Source: marketscreener.com
Astrazeneca Collaboration News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Astrazeneca Collaboration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Astrazeneca Collaboration Today - Breaking & Trending Today
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB -April 05, 2024 at 11:34 pm EDT
Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...
Source: marketscreener.com
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Application based on results from the TROPION-Breast01 phase 3 trial Additional BLA under review in the U.S. for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan for patients with...
Source: marketscreener.com
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Application based on results from the TROPION-Lung01 phase 3 trial If approved, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan may be the first TROP2 directed antibody drug conjugate...
Source: marketscreener.com
Daiichi Sankyo : Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes(241.9KB -December 18, 2023 at 08:07 am EST
Press Release Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes ...
Source: marketscreener.com